Jane Street Group LLC Buys 39,808 Shares of AlloVir, Inc. (NASDAQ:ALVR)

Jane Street Group LLC boosted its stake in AlloVir, Inc. (NASDAQ:ALVR) by 47.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 123,159 shares of the company’s stock after purchasing an additional 39,808 shares during the quarter. Jane Street Group LLC owned about 2.45% of AlloVir worth $52,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALVR. Raymond James Financial Inc. bought a new position in shares of AlloVir during the 4th quarter worth about $25,000. Northern Trust Corp raised its stake in AlloVir by 0.8% during the 4th quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after buying an additional 1,267 shares during the period. Finally, Gilead Sciences Inc. acquired a new position in AlloVir during the 4th quarter worth approximately $6,987,000. 66.05% of the stock is owned by institutional investors.

AlloVir Stock Performance

Shares of AlloVir stock opened at $3.30 on Monday. The stock has a market capitalization of $16.64 million, a PE ratio of -0.16 and a beta of 0.63. AlloVir, Inc. has a 52 week low of $7.96 and a 52 week high of $24.15. The stock has a 50 day moving average price of $5.20 and a two-hundred day moving average price of $8.47.

AlloVir Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.